### PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7335309

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	MERGER	
EFFECTIVE DATE:	12/23/2021	

#### **CONVEYING PARTY DATA**

Name	Execution Date
DOT THERAPEUTICS-2, INC.	12/22/2021
DOT THERAPEUTICS-1, INC.	12/22/2021

#### **RECEIVING PARTY DATA**

Name:	DAY ONE BIOPHARMACEUTICALS, INC.	
Street Address:	395 OYSTER POINT BLVD SUITE 217	
City:	SOUTH SAN FRANCISCO	
State/Country:	CALIFORNIA	
Postal Code:	94080	

#### **PROPERTY NUMBERS Total: 9**

Property Type	Number
Patent Number:	8293752
Patent Number:	8802657
Patent Number:	9556177
Patent Number:	9920048
Patent Number:	10426782
Application Number:	16889408
Application Number:	17180127
Patent Number:	10988469
Application Number:	63251445

#### **CORRESPONDENCE DATA**

**Fax Number:** (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6504615211
Email: cricks@wsgr.com
Correspondent Name: CHRISTINE RICKS
Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304

PATENT REEL: 059936 FRAME: 0096

507288384

ATTORNEY DOCKET NUMBER:	57841 MULTIPLE CASES	
NAME OF SUBMITTER:	CHRISTINE RICKS	
SIGNATURE:	/Christine Ricks/	
DATE SIGNED:	05/17/2022	
Total Attachments: 4		

source=DAY ONE BIOPHARMACEUTICALS INC - DE - Merger#page1.tif source=DAY ONE BIOPHARMACEUTICALS INC - DE - Merger#page2.tif source=DAY ONE BIOPHARMACEUTICALS INC - DE - Merger#page3.tif source=DAY ONE BIOPHARMACEUTICALS INC - DE - Merger#page4.tif

Page 1

# Delaware The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF
DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT
COPY OF THE CERTIFICATE OF OWNERSHIP, WHICH MERGES:

"DOT THERAPEUTICS-2, INC.", A DELAWARE CORPORATION,
"DOT THERAPEUTICS-1, INC.", A DELAWARE CORPORATION,

WITH AND INTO "DAY ONE BIOPHARMACEUTICALS, INC." UNDER THE NAME OF "DAY ONE BIOPHARMACEUTICALS, INC.", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE ON THE TWENTY-THIRD DAY OF DECEMBER, A.D. 2021, AT 6:32 O'CLOCK P.M.

7130337 8100M SR# 20214210095

Date: 12-23-21

Authentication: 205076776

You may verify this certificate online at corp.delaware.gov/authver.shtml

State of Delaware
Secretary of State
Division of Corporations
Delivered 06:32 PM 12/23/2021
FILED 06:32 PM 12/23/2021
SR 20214210095 - File Number 7130337

## STATE OF DELAWARE CERTIFICATE OF OWNERSHIP AND MERGER

#### **MERGING**

DOT Therapeutics-1, Inc. DOT Therapeutics-2, Inc. (Delaware corporations)

#### INTO

Day One Biopharmaceuticals, Inc. (a Delaware corporation)

Pursuant to Section 253 of the General Corporation Law

of the

State of Delaware (the "Delaware General Corporation Law")

Charles N. York II certifies that:

- 1. He is the Chief Operating Officer and Chief Financial Officer of Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company").
- 2. The Company owns 100% of the outstanding shares of capital stock of the following corporations incorporated under the laws of Delaware (each, a "Subsidiary," and collectively, the "Subsidiaries"):

DOT Therapeutics-1, Inc. DOT Therapeutics-2, Inc.

3. The Board of Directors of the Company (the "*Board*"), at a meeting held on December 8, 2021, duly adopted the following resolutions:

WHEREAS, each of DOT Therapeutics-1, Inc., a Delaware corporation, and DOT Therapeutics-2, Inc., a Delaware corporation (collectively, the "Subsidiaries") are wholly-owned subsidiaries of the Company; and

WHEREAS, the Board has determined that it is desirable and in the best interests of the Company to merge each of the Subsidiaries with and into the Company pursuant to a statutory short-form merger (each, a "Merger," and collectively, the "Mergers") pursuant to the provisions of Section 253 of the Delaware General Corporation Law, with the Company to be the surviving corporation of the Mergers.

NOW, THEREFORE, BE IT RESOLVED, that the Mergers are hereby approved, and that, pursuant to Section 253 of the Delaware General Corporation Law, effective as of 11:59 PM on December 31, 2021, the Company shall merge each Subsidiary with and into the Company with the Company being the surviving corporation of each Merger and, upon the effectiveness of the Mergers, the Company will acquire all the assets and properties and assume all of the liabilities and obligations of the Subsidiaries.

**RESOLVED FURTHER**, that the appropriate officers of the Company are hereby authorized and directed, on behalf of the Company, to cause the Company to execute, deliver and file one or more Certificates of Ownership and Merger with the Delaware Secretary of State, and to execute, deliver and file such additional documents (including but not limited to assumptions of franchise or other tax liability of the Subsidiaries) or perform such acts as are determined to be necessary or appropriate to carry out the Merger as described above at the appropriate time as determined by such officers.

**RESOLVED FURTHER**, that the officers of the Company, and each of them acting without the others, are hereby authorized and directed to take such further actions, and to execute and deliver such further documents as they may deem to be necessary, advisable or appropriate to carry into effect the purposes and intent of the foregoing resolutions.

[Remainder of page intentionally blank.]

IN WITNESS WHEREOF, the Company has caused this Certificate of Ownership and Merger to be executed by an authorized officer this 22<sup>nd</sup> day of December, 2021.

Charles N. York 11

By:
Name: Charles N. York II

Title: Chief Operating Officer and

Chief Financial Officer

[SIGNATURE PAGE TO CERTIFICATE OF OWNERSHIP AND MERGER]

**PATENT** 

RECORDED: 05/17/2022 REEL: 059936 FRAME: 0101